Average Return on Assets (ROA)
The latest reported return on assets (roa) is 7.75% as of Wednesday, December 31, 2025, shown against its trailing averages.
PODD Average Return on Assets (ROA)
PODD Return on Assets (ROA) Averages
RETURN ON ASSETS (ROA) LATEST REPORTED
7.75%
RETURN ON ASSETS (ROA) TTM
10.65%
RETURN ON ASSETS (ROA) 3Y
7.37%
RETURN ON ASSETS (ROA) 5Y
5.11%
RETURN ON ASSETS (ROA) 10Y
-0.39%
RETURN ON ASSETS (ROA) 15Y
-8.10%
RETURN ON ASSETS (ROA) 20Y
-18.24%
About Insulet Corp.
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Ashley A. McEvoy